OpenAI acquires Orchestra Bio to boost AI agents for drug development
OpenAI announced it has acquired Orchestra Bio, a startup that builds AI agents to help pharmaceutical companies manage drug‑development tasks. The company said the acquisition will bring Orchestra’s platform—used for delegating study monitoring, timeline tracking and delay identification—to its Rosalind suite of life‑science models and tools. Financial terms were not disclosed.
Key points
- OpenAI acquired Orchestra Bio, an AI‑agent platform for pharma drug development; terms not disclosed.
- Orchestra’s tools let scientists delegate monitoring, timeline tracking, and delay detection to AI agents, to be folded into OpenAI’s Rosalind suite.
- Anthropic’s $400 million purchase of Coefficient Bio highlights a competitive race into life‑science AI.
The move follows a broader push by AI labs into the life‑sciences sector. Anthropic bought AI biotech startup Coefficient Bio for roughly $400 million in April, and has launched Claude Science, an AI‑powered research platform. OpenAI’s own GPT‑Rosalind model, introduced in April, and partnerships with Novo Nordisk and Moderna aim to shorten the typical 10‑to‑15‑year drug‑development timeline.
Exclusive: OpenAI has acquired Orchestra Bio
finance.yahoo.com · 20 October 2026
Loading the full article…
This text was published by finance.yahoo.com and written by Madison Mills. It is reproduced here with attribution so you can read it in full; the rights remain with the publisher. Read it at the source ↗
Coverage and discussion
3sourcesThe headline, key points and digest above were generated by Digest AI's editorial model from the linked sources. Automated summaries can contain errors: the sources are the record. Spotted a mistake? Tell us. Published by Martin K., who runs Digest AI and handles corrections.
More in Business & Funding
All →- Anthropic targets November 2026 IPO at $1.5 trillion to $2 trillion valuation · 35 src
- Nscale and Anthropic reportedly in talks for second $45 billion compute deal · 15 src
- Meta seeks AI revenue proof ahead of earnings · 3 src
- Meta and Tesla face rising AI skepticism ahead of Q3 earnings · 5 src
- Morgan Stanley raises Amazon price target to $350 on AI cloud outlook · 1 src
Comments
via GitHub Discussions